|Awarded On||August 24, 2018|
|Title||Engineering Cancer Immunotherapeutics for Enhanced Activity in the Low pH Tumor Microenvironment|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Jennifer Maynard|
In spite of the exquisite specificity and high affinity of antibody-based cancer therapies, they often cause damage to healthy cells since the cancer antigens are present on healthy and tumor cells. A perfect example of this phenomenon is the widely prescribed breast cancer antibody Trastuzumab, which has significant, well-documented cardiotoxic side effects in many patients because it binds a molecule found on the surface of certain breast cancer cells and also on heart cells. If present, the heart damage is often reversible, but cardiac function is monitored throughout Trastuzumab therapy and therapy may be delayed in some severe cases. This is especially problematic for those patients who...